CL2020001826A1 - Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina. (divisional solicitud 201802416) - Google Patents
Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina. (divisional solicitud 201802416)Info
- Publication number
- CL2020001826A1 CL2020001826A1 CL2020001826A CL2020001826A CL2020001826A1 CL 2020001826 A1 CL2020001826 A1 CL 2020001826A1 CL 2020001826 A CL2020001826 A CL 2020001826A CL 2020001826 A CL2020001826 A CL 2020001826A CL 2020001826 A1 CL2020001826 A1 CL 2020001826A1
- Authority
- CL
- Chile
- Prior art keywords
- methylmethanamine
- difluorophenyl
- fluorophenyl
- sulfonyl
- methoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente invención proporciona una nueva forma cristalina I de clorhidrato, una forma cristalina II de clorhidrato, una forma cristalina de succinato, una forma cristalina de tartrato, una forma cristalina I de fumarato y una forma cristalina II de fumarato de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1H–pirrol–3–il)–N–metilmetanamina. Las nuevas formas cristalinas descriptas anteriormente tienen alta solubilidad en agua y excelente estabilidad en condiciones a prueba de humedad y en condiciones de exposición a alta humedad, y por lo tanto, pueden usarse farmacéuticamente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160036080A KR102081920B1 (ko) | 2016-03-25 | 2016-03-25 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001826A1 true CL2020001826A1 (es) | 2020-12-11 |
Family
ID=59900401
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002416A CL2018002416A1 (es) | 2016-03-25 | 2018-08-23 | Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina |
| CL2020000186A CL2020000186A1 (es) | 2016-03-25 | 2020-01-22 | Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina. (divisional solicitud 201802416). |
| CL2020001826A CL2020001826A1 (es) | 2016-03-25 | 2020-07-08 | Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina. (divisional solicitud 201802416) |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002416A CL2018002416A1 (es) | 2016-03-25 | 2018-08-23 | Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina |
| CL2020000186A CL2020000186A1 (es) | 2016-03-25 | 2020-01-22 | Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina. (divisional solicitud 201802416). |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US10336695B2 (es) |
| EP (1) | EP3433233B1 (es) |
| JP (1) | JP6554617B2 (es) |
| KR (1) | KR102081920B1 (es) |
| CN (1) | CN108602772B (es) |
| AR (1) | AR107963A1 (es) |
| AU (1) | AU2017238918B2 (es) |
| BR (1) | BR112018069461A2 (es) |
| CA (1) | CA3014745C (es) |
| CL (3) | CL2018002416A1 (es) |
| CO (1) | CO2018008833A2 (es) |
| DO (1) | DOP2018000190A (es) |
| EA (1) | EA029995B1 (es) |
| ES (1) | ES2818902T3 (es) |
| HK (1) | HK1254393A1 (es) |
| HR (1) | HRP20201594T1 (es) |
| HU (1) | HUE053502T2 (es) |
| JO (1) | JOP20170070B1 (es) |
| MA (1) | MA43833B1 (es) |
| MX (1) | MX2018009219A (es) |
| MY (1) | MY196299A (es) |
| NZ (1) | NZ745266A (es) |
| PE (1) | PE20190170A1 (es) |
| PH (1) | PH12018501846B1 (es) |
| PL (1) | PL3433233T3 (es) |
| PT (1) | PT3433233T (es) |
| RS (1) | RS60884B1 (es) |
| SG (1) | SG11201806966SA (es) |
| SI (1) | SI3433233T1 (es) |
| TN (1) | TN2018000288A1 (es) |
| TW (1) | TWI626234B (es) |
| WO (1) | WO2017164576A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102081920B1 (ko) * | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233456B1 (ko) | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102126576B1 (ko) * | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| AU2020409932B2 (en) * | 2019-12-18 | 2023-09-07 | Daewoong Pharmaceutical Co., Ltd. | Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrole-3-yl)-N-methylmethaneamine |
| CN117820193A (zh) * | 2022-09-29 | 2024-04-05 | 安徽皓元药业有限公司 | 一种非苏拉赞盐酸盐晶型a及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336107B1 (en) | 2004-09-30 | 2015-09-23 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| PL1919865T3 (pl) | 2005-08-30 | 2011-09-30 | Takeda Pharmaceuticals Co | 1-heterocyklilosulfonylo, 2-aminometylo, 5-(hetero-) arylo podstawione pochodne 1-h-pirolu jako kwasowe inhibitory wydzielania |
| WO2007114338A1 (ja) * | 2006-03-31 | 2007-10-11 | Takeda Pharmaceutical Company Limited | 酸分泌抑制薬 |
| WO2008036211A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety |
| US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| CN104718189B (zh) * | 2012-11-19 | 2017-03-15 | 江苏豪森药业集团有限公司 | 吡咯磺酰类衍生物、其制备方法及其在医药上的应用 |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| CN104447490B (zh) * | 2014-11-19 | 2017-06-06 | 连云港恒运医药有限公司 | 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途 |
| CN104447491B (zh) * | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
| KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR20170113040A (ko) | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233456B1 (ko) | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102126576B1 (ko) | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
-
2016
- 2016-03-25 KR KR1020160036080A patent/KR102081920B1/ko active IP Right Grant
-
2017
- 2017-03-17 EP EP17770546.4A patent/EP3433233B1/en active Active
- 2017-03-17 AU AU2017238918A patent/AU2017238918B2/en active Active
- 2017-03-17 PE PE2018001574A patent/PE20190170A1/es unknown
- 2017-03-17 MX MX2018009219A patent/MX2018009219A/es unknown
- 2017-03-17 SI SI201730397T patent/SI3433233T1/sl unknown
- 2017-03-17 HU HUE17770546A patent/HUE053502T2/hu unknown
- 2017-03-17 MY MYPI2018703342A patent/MY196299A/en unknown
- 2017-03-17 CN CN201780008736.5A patent/CN108602772B/zh active Active
- 2017-03-17 TN TNP/2018/000288A patent/TN2018000288A1/en unknown
- 2017-03-17 CA CA3014745A patent/CA3014745C/en active Active
- 2017-03-17 MA MA43833A patent/MA43833B1/fr unknown
- 2017-03-17 PL PL17770546T patent/PL3433233T3/pl unknown
- 2017-03-17 RS RS20201203A patent/RS60884B1/sr unknown
- 2017-03-17 NZ NZ745266A patent/NZ745266A/en unknown
- 2017-03-17 US US16/073,359 patent/US10336695B2/en active Active
- 2017-03-17 JP JP2018549562A patent/JP6554617B2/ja active Active
- 2017-03-17 ES ES17770546T patent/ES2818902T3/es active Active
- 2017-03-17 PT PT177705464T patent/PT3433233T/pt unknown
- 2017-03-17 WO PCT/KR2017/002914 patent/WO2017164576A1/en active Application Filing
- 2017-03-17 SG SG11201806966SA patent/SG11201806966SA/en unknown
- 2017-03-17 BR BR112018069461-4A patent/BR112018069461A2/pt not_active Application Discontinuation
- 2017-03-21 TW TW106109339A patent/TWI626234B/zh active
- 2017-03-22 JO JOP/2017/0070A patent/JOP20170070B1/ar active
- 2017-03-23 EA EA201790454A patent/EA029995B1/ru not_active IP Right Cessation
- 2017-03-23 AR ARP170100726A patent/AR107963A1/es unknown
-
2018
- 2018-08-23 CL CL2018002416A patent/CL2018002416A1/es unknown
- 2018-08-24 CO CONC2018/0008833A patent/CO2018008833A2/es unknown
- 2018-08-30 PH PH12018501846A patent/PH12018501846B1/en unknown
- 2018-08-31 DO DO2018000190A patent/DOP2018000190A/es unknown
- 2018-10-19 HK HK18113470.2A patent/HK1254393A1/zh unknown
-
2019
- 2019-05-14 US US16/411,270 patent/US10683268B2/en active Active
- 2019-12-18 US US16/718,300 patent/US10889545B2/en active Active
- 2019-12-18 US US16/718,286 patent/US10913715B2/en active Active
-
2020
- 2020-01-22 CL CL2020000186A patent/CL2020000186A1/es unknown
- 2020-07-08 CL CL2020001826A patent/CL2020001826A1/es unknown
- 2020-10-06 HR HRP20201594TT patent/HRP20201594T1/hr unknown
-
2021
- 2021-01-19 US US17/151,901 patent/US11459297B2/en active Active
-
2022
- 2022-07-27 US US17/874,700 patent/US11858894B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001826A1 (es) | Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina. (divisional solicitud 201802416) | |
| CY1125089T1 (el) | Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae | |
| AR109452A1 (es) | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento | |
| ECSP19036765A (es) | PROCESO PARA LA PREPARACION DE PIRAZOLO[1,5-a]PIRIMIDINAS Y SALES DE ESTAS | |
| HRP20201812T1 (hr) | Modulatori proteina jezgre hepatitisa b | |
| CL2017001249A1 (es) | Forma cristalina de sulfato de hidrógeno (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidinaa-1-il)-pirazolo[1,5-a] pirimidinaa-3-il)-3-hidroxipirrolidinaa-1-carboxamida. | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| EA201891780A1 (ru) | Производные сульфонамида и содержащие их фармацевтические композиции | |
| MY167216A (en) | Kinase inhibitors | |
| EA201401084A1 (ru) | Соли 5-[(1r)-2({2-[4-(2,2-дифтор-2-фенилэтокси)фенил]этил}амино)-1-гидроксиэтил]-8-гидроксихинолин-2(1н)-она | |
| EA201691538A1 (ru) | Способ получения солей вортиоксетина | |
| CR20180328A (es) | Compuestos de isoindol | |
| CO7151489A2 (es) | Forma amorfa de un compuesto de pirimidinilciclopentano, inhibidor akt, composiciones y métodos del mismo | |
| EA201891467A1 (ru) | Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл | |
| PE20090166A1 (es) | Sales de adicion de acido, hidratos y polimorfos de la etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas | |
| AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| AR044055A1 (es) | Monohidrocloruro de risperidona | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
| EA201792558A1 (ru) | Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль | |
| EA201791191A1 (ru) | Водные фармацевтические композиции для местного применения в ротовой полости, содержащие флурбипрофен и декспантенол | |
| CO2017007940A2 (es) | Péptidos antagonistas prgc | |
| EA202090298A1 (ru) | Способы лечения муковисцидоза | |
| AR112040A1 (es) | Sal de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1h-pirazolo[4,3-h]quinazolina-3-carboxamida, su preparación, y las formulaciones que la contienen | |
| EA201992303A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 |